Safety of ozanimod versus interferon β-1a in phase 3 studies in relapsing multiple sclerosis (sunbeam and radi-ance part B)

Category Primary study
ConferenceMultiple Sclerosis Journal
Year 2018
This article has no abstract
Epistemonikos ID: 15bc86a0bde84e7f1f47ebed6e37b30d677bf8bd
First added on: Apr 29, 2026